Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model

Andreata, F.; Bonizzi, A.; Sevieri, M.; Truffi, M.; Monieri, M.; Sitia, L.; Silva, F.; Sorrentino, L.; Allevi, R.; Zerbi, P.; Marchini, B.; Longhi, E.; Ottria, R.; Casati, S.; Vanna, R.; Morasso, C.; Bellini, M.; Prosperi, D.; Corsi, F.; Mazzucchelli, S.

doi:10.1038/s41598-020-68205-w

Neoadjuvant chemotherapy has been established as the standard of care for HER2-positive breast cancer since it allows cancer down-staging, up to pathological complete response. The standard of care in the neoadjuvant setting for HER2-positive breast cancer is a combination of highly cytotoxic drugs such as anthracyclines and the anti-HER2 monoclonal antibody. Despite this cocktail allows a pathological complete response in up to 50%, their co-administration is strongly limited by intrinsic cardiotoxicity. Therefore, only a sequential administration of anthracyclines and the anti-HER2 treatment is allowed. Here, we propose the anthracycline formulation in H-Ferritin nanocages as promising candidate to solve this unmet clinical need, thanks to its capability to increase anthracyclines efficacy while reducing their cardiotoxicity. Treating a murine model of HER2-positive breast cancer with co-administration of Trastuzumab and H-Ferritin anthracycline nanoformulation, we demonstrate an improved tumor penetration of drugs, leading to increased anticancer efficacy and reduced of cardiotoxicity.

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model / F. Andreata, A. Bonizzi, M. Sevieri, M. Truffi, M. Monieri, L. Sitia, F. Silva, L. Sorrentino, R. Allevi, P. Zerbi, B. Marchini, E. Longhi, R. Ottria, S. Casati, R. Vanna, C. Morasso, M. Bellini, D. Prosperi, F. Corsi, S. Mazzucchelli. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 10:1(2020 Jul 10), pp. 11425.1-11425.10.

Titolo:	Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model
Autori:	Andreata F. (Co-primo) BONIZZI, ARIANNA (Co-primo) SEVIERI, MARTA Truffi M. Monieri M. SITIA, LEOPOLDO Silva F. SORRENTINO, LUCA ALLEVI, RAFFAELE ENRICO ZERBI, PIETRO FRANCESCO CARLO MARCHINI, BEATRICE Longhi E. OTTRIA, ROBERTA CASATI, SARA Vanna R. Morasso C. Bellini M. Prosperi D. CORSI, FABIO RUGGERO MARIA (Penultimo) (Corresponding) MAZZUCCHELLI, SERENA (Ultimo) (Corresponding) mostra contributor esterni nascondi contributor esterni
Parole Chiave:	Breast cancer, Cardiotoxicity, Nanocages, Doxorubicin, H-Ferritin
Settore Scientifico Disciplinare:	Settore BIO/10 - Biochimica Settore MED/18 - Chirurgia Generale
Progetto:	Nanocages di ferritina per il delivery di agenti antitumorali in carcinomi mammari primari ed in metastasi cerebrali
Data di pubblicazione:	10-lug-2020
Rivista:	SCIENTIFIC REPORTS
Tipologia:	Article (author)
Digital Object Identifier (DOI):	http://dx.doi.org/10.1038/s41598-020-68205-w
Appare nelle tipologie:	01 - Articolo su periodico

File in questo prodotto:

File	Descrizione	Tipologia	Licenza
s41598-020-68205-w.pdf		Publisher's version/PDF		Open Access Visualizza/Apri

Pubblicazioni consigliate

Loading suggested articles...

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/2434/761203

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

File in questo prodotto:

Pubblicazioni consigliate